CA2171465A1 - Highly sulfated maltooligosaccharides with heparin-like properties - Google Patents

Highly sulfated maltooligosaccharides with heparin-like properties

Info

Publication number: CA2171465A1
Authority: CA; Canada
Prior art keywords: highly sulfated; sulfated; composition; compositions; heparin
Prior art date: 1993-10-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002171465A

Other languages

English (en)

French (fr)

Inventor

Peter Fugedi

David John Tyrrell

Robert James Tressler

Robert Joseph Stack

Masayuki Ishihara

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glycomed Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-07

Filing date

1994-10-04

Publication date

1995-04-13

1994-10-04 Application filed by Individual filed Critical Individual

1995-04-13 Publication of CA2171465A1 publication Critical patent/CA2171465A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 claims abstract description 30
206010028980 Neoplasm Diseases 0.000 claims abstract description 28
201000010099 disease Diseases 0.000 claims abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
201000011510 cancer Diseases 0.000 claims abstract description 10
206010038923 Retinopathy Diseases 0.000 claims abstract description 5
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 109
LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 claims description 45
OCIBBXPLUVYKCH-QXVNYKTNSA-N alpha-maltohexaose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-QXVNYKTNSA-N 0.000 claims description 16
102100024025 Heparanase Human genes 0.000 claims description 14
108010037536 heparanase Proteins 0.000 claims description 14
BNABBHGYYMZMOA-AHIHXIOASA-N alpha-maltoheptaose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O[C@@H]6[C@H](O[C@H](O)[C@H](O)[C@H]6O)CO)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O BNABBHGYYMZMOA-AHIHXIOASA-N 0.000 claims description 13
FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical class O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 claims description 13
FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 11
241001465754 Metazoa Species 0.000 claims description 10
230000012010 growth Effects 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
150000001768 cations Chemical class 0.000 claims description 8
230000002829 reductive effect Effects 0.000 claims description 8
239000002246 antineoplastic agent Substances 0.000 claims description 5
229940044683 chemotherapy drug Drugs 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
210000004204 blood vessel Anatomy 0.000 claims description 4
210000002889 endothelial cell Anatomy 0.000 claims description 4
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
208000009956 adenocarcinoma Diseases 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
210000004027 cell Anatomy 0.000 abstract description 55
230000000694 effects Effects 0.000 abstract description 55
238000005670 sulfation reaction Methods 0.000 abstract description 26
108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract description 25
102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract description 25
230000019635 sulfation Effects 0.000 abstract description 25
230000027455 binding Effects 0.000 abstract description 14
229920001542 oligosaccharide Polymers 0.000 abstract description 10
150000002482 oligosaccharides Chemical class 0.000 abstract description 9
241000699800 Cricetinae Species 0.000 abstract description 2
102000019361 Syndecan Human genes 0.000 abstract description 2
108050006774 Syndecan Proteins 0.000 abstract description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 abstract description 2
229960002897 heparin Drugs 0.000 description 50
229920000669 heparin Polymers 0.000 description 47
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 43
238000003556 assay Methods 0.000 description 23
210000000329 smooth muscle myocyte Anatomy 0.000 description 23
230000005764 inhibitory process Effects 0.000 description 22
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
229920002971 Heparan sulfate Polymers 0.000 description 20
239000002953 phosphate buffered saline Substances 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
230000004663 cell proliferation Effects 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000035755 proliferation Effects 0.000 description 12
230000010261 cell growth Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
208000014674 injury Diseases 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
239000000463 material Substances 0.000 description 8
238000011580 nude mouse model Methods 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
230000004614 tumor growth Effects 0.000 description 8
230000002792 vascular Effects 0.000 description 8
FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 8
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 7
230000033115 angiogenesis Effects 0.000 description 7
210000003711 chorioallantoic membrane Anatomy 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
DJMVHSOAUQHPSN-UHFFFAOYSA-N malto-hexaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 DJMVHSOAUQHPSN-UHFFFAOYSA-N 0.000 description 7
239000002609 medium Substances 0.000 description 7
229960000485 methotrexate Drugs 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 6
FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000007858 starting material Substances 0.000 description 6
UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
229920002683 Glycosaminoglycan Polymers 0.000 description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 5
230000001028 anti-proliverative effect Effects 0.000 description 5
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000012043 crude product Substances 0.000 description 5
229960000890 hydrocortisone Drugs 0.000 description 5
FJCUPROCOFFUSR-UHFFFAOYSA-N malto-pentaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 FJCUPROCOFFUSR-UHFFFAOYSA-N 0.000 description 5
208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
239000011593 sulfur Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000008733 trauma Effects 0.000 description 5
239000007987 MES buffer Substances 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000000964 angiostatic effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
108091016585 CD44 antigen Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
108090000054 Syndecan-2 Proteins 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
230000001780 adrenocortical effect Effects 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
229960001927 cetylpyridinium chloride Drugs 0.000 description 3
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
239000003480 eluent Substances 0.000 description 3
150000002692 maltoses Chemical class 0.000 description 3
230000014508 negative regulation of coagulation Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
208000002815 pulmonary hypertension Diseases 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
229920000045 Dermatan sulfate Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
229920001499 Heparinoid Polymers 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
-1 alkaline earth metal salts Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
229940051593 dermatan sulfate Drugs 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000002554 heparinoid Substances 0.000 description 2
229940025770 heparinoids Drugs 0.000 description 2
150000002402 hexoses Chemical class 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
229940127215 low-molecular weight heparin Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
201000005825 prostate adenocarcinoma Diseases 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001180 sulfating effect Effects 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
230000004565 tumor cell growth Effects 0.000 description 2
210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
KNBVLVBOKWRYEP-XYLDXDTCSA-N (2r,3s,4r,5r)-2-[(2r,3r,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-tris[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-3,4,5,6-tetrakis[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]hexanal Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@H]([C@@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](O[C@@H]1[C@@H]([C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 KNBVLVBOKWRYEP-XYLDXDTCSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
DIEDVCMBPCRJFQ-UHFFFAOYSA-N 10,12-tricosadiynoic acid Chemical compound CCCCCCCCCCC#CC#CCCCCCCCCC(O)=O DIEDVCMBPCRJFQ-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
238000000035 BCA protein assay Methods 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
239000005493 Chloridazon (aka pyrazone) Substances 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014523 Embolism and thrombosis Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229910003202 NH4 Inorganic materials 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
206010037457 Pulmonary vasculitis Diseases 0.000 description 1
229930182475 S-glycoside Natural products 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000005852 acetolysis reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
231100000851 acute glomerulonephritis Toxicity 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
WYKYKTKDBLFHCY-UHFFFAOYSA-N chloridazon Chemical compound O=C1C(Cl)=C(N)C=NN1C1=CC=CC=C1 WYKYKTKDBLFHCY-UHFFFAOYSA-N 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000013147 laser angioplasty Methods 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
RUJILUJOOCOSRO-WJMYNTJYSA-N maltooctaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O[C@@H]6[C@H](O[C@H](O[C@@H]7[C@H](O[C@H](O)[C@H](O)[C@H]7O)CO)[C@H](O)[C@H]6O)CO)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O RUJILUJOOCOSRO-WJMYNTJYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000008807 pathological lesion Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
229940097886 phosphorus 32 Drugs 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Ophthalmology & Optometry (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002171465A 1993-10-07 1994-10-04 Highly sulfated maltooligosaccharides with heparin-like properties Abandoned CA2171465A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13348393A	1993-10-07	1993-10-07
US08/133,483		1993-10-07

Publications (1)

Publication Number	Publication Date
CA2171465A1 true CA2171465A1 (en)	1995-04-13

Family

ID=22458825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002171465A Abandoned CA2171465A1 (en)	1993-10-07	1994-10-04	Highly sulfated maltooligosaccharides with heparin-like properties

Country Status (5)

Country	Link
EP (1)	EP0722326A4 (de)
JP (1)	JPH09503510A (de)
AU (1)	AU700451B2 (de)
CA (1)	CA2171465A1 (de)
WO (1)	WO1995009637A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN261895A0 (en) *	1995-04-28	1995-05-18	Australian National University, The	Preparation and use of sulfated oligosaccharides
AUPO556297A0 (en)	1997-03-11	1997-04-10	Australian National University, The	Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
AUPO888497A0 (en) *	1997-09-01	1997-09-25	Australian National University, The	Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
DE19747195A1 (de) *	1997-10-24	1999-04-29	Knoll Ag	Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
WO2000062785A1 (en) *	1999-04-15	2000-10-26	Takara Shuzo Co., Ltd.	Remedies
US6608042B2 (en) *	2000-03-28	2003-08-19	Aventis Pharma, S.A.	Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
CZ307433B6 (cs)	2001-09-12	2018-08-22	Leadiant Biosciences Sa	Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
US7875592B2 (en) *	2004-03-04	2011-01-25	Progen Pharmaceuticals Limited	Sulfated oligosaccharide derivatives
CN100363373C (zh) *	2005-01-14	2008-01-23	庄茅	异麦芽低聚糖硫酸酯（imos）的制备方法
CA2704201C (en) *	2007-10-16	2015-06-30	Progen Pg500 Series Pty Ltd	Novel sulfated oligosaccharide derivatives
EP2809326B1 (de) *	2012-01-30	2018-07-25	Baxalta GmbH	Nicht-antikoagulierende sulfatierte oder sulfonierte polysaccharide
CN104334714A (zh)	2012-03-30	2015-02-04	味之素株式会社	含硫酸化化合物的干细胞增殖用培养基
US11787783B2 (en)	2016-12-13	2023-10-17	Beta Therapeutics Pty Ltd	Heparanase inhibitors and use thereof
BR112019012045A2 (pt)	2016-12-13	2020-08-18	Beta Therapeutics Pty Ltd	inibidores de heparanase e uso dos mesmos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4021544A (en) *	1976-07-12	1977-05-03	American Cyanamid Company	Complement inhibitors
US4066829A (en) *	1976-07-12	1978-01-03	American Cyanamid Company	Malto-dextrin poly(H-)sulfates
JPS56108713A (en) *	1980-02-01	1981-08-28	Nippon Kayaku Co Ltd	Antitumor preparation
US4435387A (en) *	1982-10-25	1984-03-06	American Cyanamid Company	Poly-cation salts of bis (or tris) 4-O-polyhexose-thio-arylene sulfate derivatives
JPS5951583A (ja) *	1983-06-15	1984-03-26	Nippon Telegr & Teleph Corp <Ntt>	半導体レ−ザ装置
US4470976A (en) *	1983-08-29	1984-09-11	American Cyanamid Company	Poly-cation salt of 4-O-polyhexaose-thio-arylene sulfates
IL85145A (en) *	1987-01-23	1994-08-26	Univ Australian	Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
WO1989003684A1 (fr) *	1987-10-30	1989-05-05	Chugai Seiyaku Kabushiki Kaisha	Agent anti-vih
JPH036457A (ja) *	1989-06-02	1991-01-11	Koyo Seiko Co Ltd	車輪回転速度検出器を備えた車軸用軸受装置
JP2792914B2 (ja) *	1989-06-02	1998-09-03	光洋精工株式会社	車輪回転速度検出器を備えた車軸用軸受装置
JP2956090B2 (ja) *	1989-10-30	1999-10-04	大日本インキ化学工業株式会社	オリゴ糖誘導体
US5298616A (en) *	1990-10-03	1994-03-29	Hoffmann-La Roche Inc.	Sulfated O-polysaccharide-trehaloses

1994
- 1994-10-04 EP EP94931314A patent/EP0722326A4/de not_active Withdrawn
- 1994-10-04 WO PCT/US1994/011368 patent/WO1995009637A1/en not_active Ceased
- 1994-10-04 AU AU80136/94A patent/AU700451B2/en not_active Ceased
- 1994-10-04 JP JP7511029A patent/JPH09503510A/ja active Pending
- 1994-10-04 CA CA002171465A patent/CA2171465A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JPH09503510A (ja)	1997-04-08
EP0722326A4 (de)	1999-10-06
AU8013694A (en)	1995-05-01
WO1995009637A1 (en)	1995-04-13
EP0722326A1 (de)	1996-07-24
AU700451B2 (en)	1999-01-07

Legal Events

Date	Code	Title	Description
2000-10-04	FZDE	Dead

Publication	Publication Date	Title
US5739115A (en)	1998-04-14	Sulfated maltooligosaccharides with heparin-like properties
US5250519A (en)	1993-10-05	Non-anticoagulant heparin derivatives
US5296471A (en)	1994-03-22	Method for controlling o-desulfation of heparin and compositions produced thereby
US5380716A (en)	1995-01-10	Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5795875A (en)	1998-08-18	Therapeutic methods of using O-desulfated heparin derivatives
US5696100A (en)	1997-12-09	Method for controlling O-desulfation of heparin and compositions produced thereby
EP0577756A1 (de)	1994-01-12	Neue nicht-antikoagulierende heparinderivate
AU700451B2 (en)	1999-01-07	Highly sulfated maltooligosaccharides with heparin-like properties
EA001199B1 (ru)	2000-12-25	Сульфатированный олигосахарид, его применение для лечения теплокровных животных и фармацевтическая композиция на его основе
WO1996006867A9 (en)	1996-05-23	Method for controlling o-desulfation of heparin and compositions produced thereby
KR20040048404A (ko)	2004-06-09	혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체
US4966894A (en)	1990-10-30	Polysulfated heparins for treating diseases caused by retroviruses
US5464827A (en)	1995-11-07	Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
EP0769502B1 (de)	2003-10-15	Verfahren zur herstellung von desulfatiertem polysaccharid und desulfatiertem heparin
HRP931389A2 (en)	1995-04-30	Compositions for the regulation of cytokine activity
EP0582665A1 (de)	1994-02-16	Sulfatierte polysaccharide als hemmungsmittel zur glatten-muskelzellen-wucherung
WO2005092348A1 (ja)	2005-10-06	ヘパリン様オリゴ糖含有ｈｇｆ産生促進薬剤
JPH02124902A (ja)	1990-05-14	血液凝固抑制剤